The pursuit of effective treatments for Maternally Inherited Diabetes and Deafness (MIDD) has taken a significant leap forward with the development of mitoARCUS, a mitochondrial-targeted nuclease designed to eliminate the pathogenic m.3243A>G mutation.
MIDD and other related mitochondrial diseases are caused by heteroplasmic mutations, where mutant and wild-type mitochondrial DNA (mtDNA) coexist within the same cell. The therapeutic strategy involves preferentially cleaving and degrading the mutant mtDNA, allowing the residual wild-type genomes to repopulate the cell and shift the heteroplasmy below the disease-causing threshold.
Researchers have engineered mitoARCUS from the naturally occurring I-CreI endonuclease. Unlike other gene-editing technologies that suffer from limitations related to size and specificity, mitoARCUS benefits from a small, single-component protein structure and high specificity. In recent studies, mitoARCUS robustly eliminated m.3243A>G mutant mtDNA without cutting wild-type mtDNA. This specific cleavage allowed for significant shifts in heteroplasmy, leading to concomitant improvements in mitochondrial protein steady-state levels and cellular respiration.
Crucially, the in vivo efficacy of mitoARCUS was demonstrated using an m.3243A>G xenograft mouse model. The nuclease was delivered systemically via adeno-associated virus (AAV9) vectors, successfully targeting the mutant genomes in living organisms. These findings strongly support the continued development of mitoARCUS as an in vivo gene-editing therapeutic, providing a potential pathway to halt or reverse the progression of MIDD and significantly improve patient outcomes.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.